The IPOX® Week, April 20, 2020

  • As equities try to heal from COVID-19 impact, lack of exposure to the New Generation of stocks leaves conventional benchmarks with significant absolute and relative losses.
  • Ahead of earnings, IPOX Indexes record strong gains across the board; IPOX China (CNI) turns positive YTD.
  • Biopharma Akeso (9926 HK) set for Hong Kong trading debut.

As equities heal from COVID-19 impact, lack of exposure to the New Generation of stocks leaves conventional benchmarks with significant absolute and relative losses YTD: Amid lower equity risk (VIX: -8.45%) and COVID-19 containment progress, the IPOX Indexes topped the global equity indexes rankings during U.S. options expiration week. Strength was broad-based and extended across IPOX Regions and Sectors. On the global level, e.g., the IPOX Global (IPGL50) – a basket of the largest global New Listings by applying the IPOX Indexes Technology – surged +6.89% to -2.39% YTD, now +1187 bps. ahead of global market YTD. By carrying 37.12% (14.03%) exposure to unique Europe-domiciled firms (including the world’s most innovative Nordic region), strong gains were be recorded by the diversified IPOX International (ETF: FPXI), which added +5.41% to -0.94% YTD, and extending the YTD lead vs. the International Market to a massive +1959 bps.

Investing in the New Generation of Stocks with “FPXI”:

IPOX China (CNI) turns positive YTD: We also note another good week for the broad-based, diversified IPOX China Core (CNI), adding +3.96% to +3.32% YTD. Companies leading the strong showing included $1.95 billion meat producer Cofco Meat (1610 HK: +29.65%), $3.38 billion electric car maker Nio (NIO US: +20.22%) and $12.7 billion GDS Holdings (GDS US: +15.96%), a leading developer and operator of high performance data centers.

Significant IPOX Holdings set to report earnings this week:

Name Ticker ETF Date
SNAP SNAP US FPX 4/21 (Aft-mkt U.S.)
TELE2 TEL2B SS FPXI 4/21
BIOGEN BIIB US FPX 4/22 (Bef-mkt U.S.)
THERMO FISHER TMO US FPX 4/22 (Bef-mkt U.S)
HERSHEY HSY US FPX 4/23 (Bef-mkt U.S.)
ELI LILLY LLY US FPX 4/23 (Bef-mkt U.S.)
SAFEHOLD SAFE US FPX 4/23 (Bef-mkt U.S.)
EVOLUTION GAMING EVO SS FPXI 4/23
VERIZON VZ US FPX 4/24 (Bef-mkt U.S.)
Long-only IPOX® Indexes Price Returns (%) Last Week 2019 2020 YTD
IPOX® Indexes: Global/International
IPOX® Global (IPGL50) (USD) 6.89 27.93 -2.39
IPOX® International (IPXI)* (USD) (ETF: FPXI) 5.41 31.37 -0.94
IPOX® Indexes: United States
IPOX® Composite U.S. (USD) 4.58 24.64 -8.81
IPOX® 100 U.S. (IPXO)* (USD) (ETF: FPX) 5.40 29.60 -12.14
IPOX® ESG (IPXT) (USD) 5.38
IPOX® Indexes: Europe/Nordic
IPOX® 30 Europe (IXTE) (EUR) 3.02 34.55 -0.97
IPOX® Nordic (IPND) 2.19 38.52 -4.28
IPOX® 100 Europe (IPOE)* (USD) 2.63 30.97 -10.34
IPOX® Indexes: Asia-Pacific/China
IPOX® Asia-Pacific (IPTA) (USD) 6.37 4.41 -5.87
IPOX® China (CNI) (USD) 3.96 26.31 3.32
IPOX® Japan (IPJP)** (JPY) 5.79 37.91 -15.77

* Basis for ETFs: FPX US, FPX LN, FPXE US, FPXU FP, FPXI US, TCIP110 IT and CME-traded e-mini IPOX® 100 U.S. Futures (IPOM0). Source: Bloomberg L.P. & Refinitiv/Thomson Reuters. For IPOX Alternative Strategies Returns, please contact [email protected]

NOW TRADING: 0.25 tick IPOX 100 U.S. Index Futures (Front month: IPOM0). Whether you are a risk manager or speculator, CME Group – the world’s largest exchange operator – now offers efficient and cost-effective access to the IPOX 100 U.S. Index (ETF: FPX) via emini IPOX 100 U.S. Index Futures (Front month: IPOM0). Contact [email protected] for further info and Free Data & Resources.


IPOX’s biggest Winners and Losers (Last Week in %):
MODERNA INC 47.05 BRIGHTHOUSE FINANCIAL -17.88
SHOPIFY INC 41.33 AIB GROUP -15.06
ROKU INC 37.16 ADEVINTA -14.22
BAYCURRENT CONSULTING 35.90 BAWAG GROUP -13.75
TESLA 31.57 ARCONIC -12.23
COFCO MEAT HOLDINGS 29.65 HOWMET AEROSPACE -12.08
CARVANA 27.24 JDC -12.04
EQT 23.57 USEN NEXT HOLDINGS -10.97
MERCARI 23.47 INWIDO -10.37
APELLIS PHARMA 23.34 APPLE HOSPITALITY REIT -9.85
SANSAN 23.21 SIGNIFY -9.34
COUPA SOFTWARE 22.51 UNIVAR SOLUTIONS -9.08
EVERBRIDGE 22.26 CORTEVA -8.66
ONE LIFE HEALTHCARE 19.79 CLOUDERA -7.55

IPO Deal-flow Review and Outlook: Biopharma Akeso (9926 HK) set for Hong Kong trading debut. Amid COVID-19, IPO activity amongst biopharma companies remained brisk with Hong Kong listed Akeso (9926 HK) lined up for this week. Other IPO News include: 1) Apollo’s cloud services unicorn Rackspace filed confidential documents for a re-IPO, followed by Chinese software maker veteran Kingsoft’s cloud services spin-off Kingsoft Cloud; 2) fantasy sports and sports-betting provider DraftKings to proceed reverse-IPO plan; 3) Tencent-backed mobile game developer Archosaur to list in HK; 4) multiple Brazilian IPOs including Warburg-backed pet store Petz to IPO towards year-end and 5) micro-cap COVID-19 test maker Atomo Diagnostics (AT1 AU: +160.0%) surges in ASX launch.

Lime Brokerage LLC is not affiliated with these service providers. Data, information, and material (“content”) is provided for informational and educational purposes only. This content neither is, nor should be construed as an offer, solicitation, or recommendation to buy or sell any securities. Any investment decisions made by the user through the use of such content is solely based on the users independent analysis taking into consideration your financial circumstances, investment objectives, and risk tolerance. Lime Brokerage LLC does not endorse, offer or recommend any of the services nor information provided by any of the above service providers and any service or information used to execute any trading strategies are solely based on the independent analysis of the user.

You may also be interested in...

Why European Investors Interested In US ETFs Are Turning To US Brokers
Read More
The IPOX® Week, August 3rd, 2020
Read More
The Tech Trade Cools Off With Earnings On Deck
Read More
The IPOX® Week, July 27, 2020
Read More

Try the demo

Compare Platforms
Check the background of this firm on FINRA's BrokerCheck

Our website uses cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site in our Privacy Policy. By clicking OK, you agree to allow us to collect information through cookies.

OK